About our Oncology efforts
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.
Selection of projects in February 2024
Phase 1 studies are usually designed with an emphasis on the assessment of safety and tolerability of an investigational drug in a small group of people for the first time. It can include healthy participants or participants with the disease.
STING agonist (2nd generation)
B7-H6/CD3 T-Cell Engager
VSV-GP
KISIMA® cancer vaccine
Ezabenlimab
SIRPα antagonist
CD137/FAP agonist
Brigimadlin
DLL3/CD3 T-cell engager
Modified yersinia
KRAS multi-inhibitor
Phase 2 studies are usually designed to begin to evaluate the efficacy of an investigational drug in a higher number of participants with the disease, and often used to obtain dose-ranging information. Safety also continues to be assessed during this phase.
Brigimadlin (BI 907828)
BI 764532
BI 764532
BI 764532
Brigimadlin (BI 907828)
Phase 3 studies are designed to confirm the data of Phase 2 studies for an investigational drug. Large numbers of participants with the disease are generally involved to obtain safety and efficacy data to evaluate the overall benefit-risk relationship of an investigational drug to provide an adequate basis for regulatory approvals. Given the size of these studies and to ensure a representative sample of patients, they are often conducted across several countries.
Zongertinib (BI 1810631)
Indication abbreviations
BTC: advanced biliary tract cancer
DDLPS: Dedifferentiated liposarcoma
ep-NEC: Extra-pulmonary neuroendocrine carcinoma
NSCLC: Non-small-cell lung cancer
SCLC: Small-cell lung cancer
LC-NEC: large cell neuroendocrine carcinoma